查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971502

雙特異性抗體市場－全球產業規模、佔有率、趨勢、機會和預測：按適應症、地區和競爭格局分類，2021-2031年

Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球雙特異性抗體市場預計將從 2025 年的 74.4 億美元成長到 2031 年的 127.6 億美元，年複合成長率為 9.41%。

這些療法是經過特殊設計的蛋白質，能夠同時結合兩種不同的抗原或抗原決定位，從而提供全新的作用機制，例如引導免疫效應細胞到達腫瘤部位。這種雙標靶化能力，加上蛋白質工程技術的進步克服了單特異性抗體的局限性，正推動其在腫瘤學和自體免疫疾病治療領域的應用日益廣泛。抗體學會指出，2023年美國和歐洲監管機構核准了首批四種雙特異性抗體，凸顯了該領域快速的商業性化進展。

市場概覽
預測期 2027-2031
市場規模：2025年 74.4億美元
市場規模：2031年 127.6億美元
複合年成長率：2026-2031年 9.41%
成長最快的細分市場 癌症
最大的市場 北美洲

然而，該市場在生產複雜性和擴充性方面面臨重大挑戰。合成雙特異性抗體需要複雜的製程以確保正確的鏈配對和穩定性，這導致其產量低於傳統單株抗體，成本更高。這些技術壁壘使得規模化生產困難，並需要嚴格的品管措施。這些要求可能會延遲監管核准，增加最終治療成本，並阻礙其廣泛市場准入。

市場促進因素

生物技術領域的策略合作和授權協議正在從根本上改變產業結構，製藥巨頭積極收購外部創新成果以增強其免疫腫瘤產品組合。主要企業透過收購成熟的雙特異性抗體平台來降低早期研發風險，這些平台能夠同時針對多種疾病路徑。這一趨勢正在催生一個生態系統，在這個系統中，中小型生物技術公司可以獲得必要的資金，而大型公司則可以為其研發管線鎖定有前景的候選藥物。例如，根據 Fierce Biotech 報導，默克於 2024 年 1 月簽署了一項最終協議，以約 6.8 億美元收購 Harpoon Therapeutics，從而進入許可權該公司專有的 T 細胞活化技術。

新型雙特異性療法的監管核准激增，進一步推動了市場發展，因為這些複雜的治療方法已在廣泛的患者群體中展現出安全性和有效性。隨著生產和臨床通訊協定標準化的推進，監管機構正在加快核准，這些治療方法正從實驗階段走向主流臨床實踐。據抗體協會稱，包括tarlatamab和zanidatamab在內的幾種新型雙特異性抗體藥物於2024年首次核准。監管方面的成功凸顯了其商業性可行性，羅氏公司在2024年10月宣布，其雙特異性抗體藥物Vabysmo在當年九個月的年銷售額已達到28億瑞士法郎，便印證了這一點。

市場挑戰

生產流程的複雜性和規模化生產的困難仍然是全球雙特異性抗體市場擴張的主要障礙。與標準單株抗體不同，雙特異性抗體需要精確設計兩個不同的結合位點，而這個過程本身就增加了錯配和產品不穩定的風險。這種技術複雜性通常會導致產量降低和雜質含量升高，從而直接推高產品成本。因此，製造商在將生產規模擴大到商業水平時面臨許多困難，而高昂的價格限制了患者獲得治療的機會，阻礙了市場滲透。

此外，這些生產挑戰需要嚴格的品管措施，導致研發週期延長和監管批准延遲。為確保這些複雜分子的穩定性和安全性，需要進行嚴格的審查，這也導致了後期研發階段的高失敗率。根據抗體協會估計，到2024年，抗體療法的整體核准成功率預計在14%至32%之間，這反映出巨大的研發風險和監管障礙阻礙了此類複雜治療方法的快速商業化，並減緩了市場成長速度。

市場趨勢

出於提高病患就醫便利性和最佳化醫療資源利用的需求，市場正明顯轉向皮下給藥製劑。製造商正積極重新設計靜脈注射療法，使其適用於皮下給藥，旨在縮短治療時間、簡化給藥流程並減輕慢性治療方法的後勤負擔。這一趨勢得到了臨床證據的支持。強生表示，2024年5月公佈的III期PALOMA-3試驗數據顯示，與靜脈注射注射相比，皮下注射的阿米伐他單抗可將液體相關反應減少五分之一，並將給藥時間縮短至約5分鐘。

同時，隨著研發公司將這些治療方法轉向高發自自體免疫疾病領域，一個顯著的趨勢正在顯現：適應症範圍從腫瘤領域向其他領域多元化發展。雖然腫瘤仍然是主要領域，但精準清除致病性B細胞和調節雙重發炎路徑的能力正在推動對非癌症領域（例如異位性皮膚炎和類風濕性關節炎）的投資增加。默克在2024年8月達成協議，以最高13億美元收購Curon Biopharmaceuticals公司處於臨床階段的雙特異性抗體CN201，就是這項策略擴張的典型例子。該公司明確計劃將該資產用於治療B細胞相關的自體免疫疾病。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球雙特異性抗體市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（癌症、發炎/自體免疫疾病及其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美雙特異性抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲雙特異性抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區雙特異性抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲雙特異性抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲雙特異性抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球雙特異性抗體市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Akeso Inc
  • Johnson & Johnson Private Limited
  • Taisho Pharmaceutical Co Ltd
  • Immunocore Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17639

The Global Bispecific Antibodies Market is projected to expand from USD 7.44 Billion in 2025 to USD 12.76 Billion by 2031, reflecting a compound annual growth rate of 9.41%. These therapeutics are engineered proteins capable of binding simultaneously to two distinct antigens or epitopes, offering novel mechanisms of action such as redirecting immune effector cells to tumor sites. This dual-targeting capability drives their increasing adoption in oncology and autoimmune disease treatments, supported by advances in protein engineering that surpass the limitations of monospecific options. The rapid commercial progression of this sector was highlighted by The Antibody Society, which noted that regulatory agencies in the United States and Europe granted first approvals to four bispecific antibodies in 2023.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.44 Billion
Market Size 2031USD 12.76 Billion
CAGR 2026-20319.41%
Fastest Growing SegmentCancer
Largest MarketNorth America

However, the market faces substantial challenges regarding manufacturing complexity and production scalability. Synthesizing bispecific antibodies involves intricate processes to ensure correct chain pairing and stability, often resulting in lower yields and higher costs compared to conventional monoclonal antibodies. These technical hurdles make upscaling production difficult and necessitate stringent quality control measures. Such requirements can delay regulatory clearance and inflate the final cost of therapy, potentially impeding widespread market accessibility.

Market Driver

Strategic collaborations and licensing agreements within the biotechnology sector are fundamentally reshaping the landscape as pharmaceutical giants aggressively acquire external innovation to strengthen their immuno-oncology portfolios. Major players are mitigating early-stage development risks by purchasing established bispecific platforms capable of targeting multiple disease pathways simultaneously. This trend fosters an ecosystem where smaller biotechs receive essential capital while larger firms secure high-potential candidates for their pipelines. For example, according to Fierce Biotech, Merck entered a definitive agreement in January 2024 to acquire Harpoon Therapeutics for approximately $680 million to access its proprietary T-cell engager technology.

A surge in regulatory approvals for novel bispecific therapies further drives the market, validating the safety and efficacy of these complex modalities for broader patient populations. As manufacturing and clinical protocols standardize, regulatory bodies are accelerating authorizations, moving these treatments from experimental stages to mainstream practice. The Antibody Society noted that in 2024, agencies granted first approvals to several new bispecifics, including tarlatamab and zanidatamab. This regulatory success supports commercial viability, as evidenced by Roche's report in October 2024 that sales of its bispecific medicine Vabysmo reached CHF 2.8 billion in the first nine months of the year.

Market Challenge

The complexity of manufacturing and production scalability remains a significant barrier to the expansion of the Global Bispecific Antibodies Market. Unlike standard monoclonal antibodies, bispecific formats require the precise engineering of two distinct binding arms, a process that inherently increases the risk of chain mispairing and product instability. These technical intricacies frequently result in lower production yields and higher levels of impurities, which directly escalate the cost of goods sold. Consequently, manufacturers face difficulties in upscaling processes to commercial levels, leading to high pricing structures that limit therapy accessibility and market penetration.

Moreover, these production hurdles necessitate stringent quality control measures that extend development timelines and delay regulatory decision-making. The rigorous scrutiny required to ensure the stability and safety of these complex molecules contributes to a high attrition rate during late-stage development. According to The Antibody Society, the overall approval success rates for antibody therapeutics in 2024 were estimated to range between 14% and 32%, reflecting the substantial developmental risks and regulatory hurdles that impede the rapid commercialization of such complex modalities and slow the market's growth trajectory.

Market Trends

The market is experiencing a definitive shift towards subcutaneous delivery formulations, driven by the need to enhance patient convenience and optimize healthcare resource utilization. Manufacturers are actively re-engineering intravenous therapies into subcutaneous formats to significantly reduce chair time and administration complexity, addressing the logistical burdens of chronic treatment regimens. This trend is supported by clinical evidence; according to Johnson & Johnson, data from the Phase 3 PALOMA-3 study in May 2024 demonstrated that the subcutaneous formulation of amivantamab reduced infusion-related reactions five-fold compared to the intravenous version while shortening administration time to approximately five minutes.

Concurrently, there is a major trend regarding the diversification of indications beyond oncology, as pharmaceutical developers pivot these modalities toward high-prevalence autoimmune disorders. While oncology remains a key area, the ability of bispecific antibodies to precisely deplete pathogenic B-cells or modulate dual inflammatory pathways has triggered increased investment in non-cancer applications such as atopic dermatitis and rheumatoid arthritis. This strategic expansion is exemplified by Merck & Co.'s agreement in August 2024 to acquire Curon Biopharmaceutical's clinical-stage bispecific antibody CN201 for a potential $1.3 billion, explicitly aiming to leverage the asset for treating B-cell associated autoimmune diseases.

Key Market Players

  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Akeso Inc
  • Johnson & Johnson Private Limited
  • Taisho Pharmaceutical Co Ltd
  • Immunocore Ltd

Report Scope

In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bispecific Antibodies Market, By Indication

  • Cancer
  • Inflammatory & Autoimmune Disorders
  • Others

Bispecific Antibodies Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.

Available Customizations:

Global Bispecific Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bispecific Antibodies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Bispecific Antibodies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bispecific Antibodies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
    • 6.3.2. Canada Bispecific Antibodies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
    • 6.3.3. Mexico Bispecific Antibodies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication

7. Europe Bispecific Antibodies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bispecific Antibodies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
    • 7.3.2. France Bispecific Antibodies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
    • 7.3.3. United Kingdom Bispecific Antibodies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
    • 7.3.4. Italy Bispecific Antibodies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
    • 7.3.5. Spain Bispecific Antibodies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication

8. Asia Pacific Bispecific Antibodies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bispecific Antibodies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
    • 8.3.2. India Bispecific Antibodies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
    • 8.3.3. Japan Bispecific Antibodies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
    • 8.3.4. South Korea Bispecific Antibodies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
    • 8.3.5. Australia Bispecific Antibodies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication

9. Middle East & Africa Bispecific Antibodies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bispecific Antibodies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
    • 9.3.2. UAE Bispecific Antibodies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
    • 9.3.3. South Africa Bispecific Antibodies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication

10. South America Bispecific Antibodies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bispecific Antibodies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
    • 10.3.2. Colombia Bispecific Antibodies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
    • 10.3.3. Argentina Bispecific Antibodies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bispecific Antibodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Amgen Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd
  • 15.3. Genentech Inc
  • 15.4. Akeso Inc
  • 15.5. Johnson & Johnson Private Limited
  • 15.6. Taisho Pharmaceutical Co Ltd
  • 15.7. Immunocore Ltd

16. Strategic Recommendations

17. About Us & Disclaimer